Search | Clinical Trials Finder

Conditions: Healthy
Interventions: Lansoprazole, Prevacid®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy
Interventions: Nisoldipine Extended-release Tablets, 40 mg, Sular Tablets, 40 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Substance Use, HIV Infections, HCV Infection, Sexually Transmitted Infections (Not HIV or Hepatitis), Overdose, Drug, Opioid Use
Interventions: Health Linkage, Overdose Education; Behavioral
Lead sponsor: April M Young; Other
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease
Interventions: CT Coronary Angiography (CTCA), Traditional Strategy; Diagnostic Test · Procedure
Lead sponsor: American College of Radiology; Other
Eligibility: 30 Years and older
Enrollment: 1,392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Winston-Salem, North Carolina • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 1 more

Conditions: Lung Carcinoma
Interventions: Educational Intervention, Exercise Intervention, Medical Device Usage and Evaluation, Physical Performance Testing, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Davis, California • Duarte, California • Irvine, California + 13 more

Conditions: Healthy
Interventions: KADIAN (morphine sulfate sustained-release) capsules, Avinza (morphine sulfate sustained-release) capsules; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Subjects
Interventions: Experimental paracetamol formulation, Marketed paracetamol, Higher dose marketed paracetamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions: Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx); Drug · Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 40
States / cities: Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more

Conditions: Healthy
Interventions: DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Acute Myocardial Infarction, Acute Coronary Syndrome
Interventions: Cardiac Troponin Testing; Diagnostic Test
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 21 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: PCOS
Interventions: OCP + Metformin, OCP + Placebo, Metformin + Placebo; Drug
Lead sponsor: Anuja Dokras; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Calcium Release Deficiency Syndrome (CRDS)
Interventions: Pacing; Diagnostic Test
Lead sponsor: Population Health Research Institute; Other
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 1 more

Conditions: Healthy Volunteers
Interventions: Decitabine-THU; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: PTSD, Substance Use Disorder (SUD), Acute Stress Disorder
Interventions: ASSIST Video Intervention; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 12 Years to 17 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Periodontal Diseases
Interventions: Connective Tissue Graft Technique, Pinhole Surgical Technique; Procedure
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 19 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hematopoietic and Stem Cell Transplant
Interventions: General Health Module-Baseline Adolescent-Self Report (13-18 years), General Health Module-Follow Up Adolescent-Self Report (13-18 years), General Health Module-Baseline Parent Report-Adolescent (13-18 years), General Health Module-Follow Up Parent Report-Adolescent (13-18 years), General Health Module-Baseline Parent Report-School Age (5-12 years), General Health Module-Follow Up Parent Report-School Age (5-12 years), Demographic Data Form, SCT Daily Activity Log, The Functional Independence Measure for Children, Manual Muscle Testing, 3-Minute Step Test, HSCT Module-Follow Up Adolescent-Self Report (13-18 years), HSCT Module-Follow Child-Self Report (5-12 years), HSCT Module-Follow Up Parent Report-adolescent (13-18 years), HSCT Module-Follow Up Parent Report-School Age (5-12 years); Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 7 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Stroke, Stroke Sequelae, Stroke/Brain Attack
Interventions: Magnetoencephalography (MEG); Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 55 participants
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fat Consumption, Inflammatory Markers
Interventions: Inflammatory markers test in blood prior to surgery, Inflammatory markers test in CSF (cerebrospinal fluid), MOCA test, CAM-3D; Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 60 Years and older
Enrollment: 62 participants
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Gonorrhea Male
Interventions: Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine; Drug · Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Multiple Sclerosis, Neuropathic Pain
Interventions: glibenclamide, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Latent Tuberculosis Infection, Tuberculosis
Interventions: Not listed
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: Not listed
Enrollment: 21,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 10
States / cities: Phoenix, Arizona • Richmond, California • Denver, Colorado + 7 more

Conditions: COPD, Asthma
Interventions: Benefits investigation; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Suicidal Ideation, Suicide, Attempted
Interventions: ASAP (As Safe As Possible), BRITE smart phone app, TAU (treatment as usual); Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 17 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Dallas, Texas

Conditions: Healthy
Interventions: Oxycodone hydrochloride tablet 15 mg, Roxicodone™ tablet 15 mg; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Search by objective public record fields.

Lansoprazole 30 mg DR Capsule Replicate Food Study

Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers

Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)

Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)

Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults

A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

Safe Emergency Department DIscharGE Rate (SEIGE)

Comparing the Effects of Oral Contraceptive Pills Versus Metformin

Evaluation of A Clinical Diagnostic Test for CRDS

A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People

Adolescent Stress and Substance Intervention Subsequent to Trauma

Pinhole Surgical Technique Compared to Connective Tissue Graft in Treatment of Gingival Recession

Deconditioning in Transplant

Imaging Post-Stroke Recovery: Using MEG to Evaluate Cognition

Preoperative Dietary Fat Consumption and Baseline Inflammatory Markers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis

A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)

Establishing Efficacy of an Inpatient Intervention and Phone App to Reduce Suicidal Risk

Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets